Lung Cancer (Samsung Medical Center, 2016)
Overview
Lung cancer cohort from Samsung Medical Center (South Korea, 2016), used as a validation dataset in multi-cancer RNA-based tumor classification studies. Included as one of 41 non-TCGA datasets in the ATLAS classifier validation set. PMID:27634761
Composition
- Lung cancer patients from Samsung Medical Center; included as part of the non-TCGA validation cohort (N=6,820 across 41 datasets) in the ATLAS classifier study. PMID:27634761
- Cancer types include NSCLC (lung adenocarcinoma LUAD and squamous cell carcinoma LUSC). PMID:27634761
Assays / panels (linked)
- RNA-seq used for tumor lineage and site classification. PMID:27634761
Papers using this cohort
- PMID:27634761 — A platform-independent AI tumor lineage and site (ATLAS) classifier.
Notable findings derived from this cohort
- Contributed to multi-dataset validation of the ATLAS classifier, which achieved 91.4% overall accuracy for cancer site of origin (22 classes) and 97.1% for cancer lineage (8 classes) across 10,376 validation samples. PMID:27634761
Sources
- cBioPortal study
lung_smc_2016PMID:27634761.
This page was processed by entity-page-writer on 2026-04-11.